RESUMEN
@#[摘 要] 近年来，肿瘤新抗原掀开了个体化免疫治疗的新篇章，作为基于新抗原个体化免疫治疗的重要组成部分，新抗原特异性T细胞的过继输注（ACT）疗法备受瞩目。本文将首先从新抗原特异性T细胞ACT治疗应用策略及临床应用现状介绍新抗原特异性T细胞ACT治疗这一新兴的精准免疫治疗的发展现状，然后从新抗原的预测、新抗原特异性T细胞筛选及扩增等方面系统地总结新抗原T细胞ACT治疗所面临的阻碍和挑战，最后从优化新抗原预测、增加新抗原特异性T细胞数量和多样性、防止新抗原特异性T细胞过度分化或死亡、缩短生产周期和减少生产成本及探索联合治疗方式等五个方面对该领域的未来发展机遇和研究方向进行重点阐述。
RESUMEN
Anti-apoptosis plays an important role in tumour formation and development. Survivin is a member of the inhibitor of apoptosis (IAP) family, which is a target for anti-cancer drug exploitation was replaced as development. We investigated the role of the homo dominant-negative mutant Survivin-T34A in suppressing human lung adenocarcinomas (A549). The anti-tumour activity of HSurvivinT34A plasmid was evaluated in the A549 cell line and nude mice bearing A549 subcutaneous tumours. Low-dose systemic administration was continuously used. The HSurvivinT34A plasmid (5 μg/one) complexed with a cationic liposome (DOTAP/Chol) signifi cantly inhibited tumour growth in our model. We observed microvessel density degradation by CD31 immunohistochemistry and apoptotic cell increase by TUNEL assay, PI staining and fl ow cytometric analysis in the treated group. The present fi ndings suggest that the HSurvivinT34A plasmid complexed with a cationic liposome may provide an effective approach to inhibit the growth of human lung adenocarcinomas in vitro and in vivo.
RESUMEN
Suberonylanilide hydroxamic acid (SAHA)is an orally administered histone deacetylase inhibitor (HDACI) that has shown significant antitumour activity in a variety of tumour cells.To identify proteins involved in its antitumour activity,we utilized a proteomic approach to reveal protein expression changes in the human cervical cancer cell line HeLa following SAHA treatment.Protein expression profiles were analysed by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and protein identification was performed on a MALDI-Q-TOF MS/MS instrument.As a result,a total of nine differentially expressed proteins were visualized by 2-DE and Coomassie brilliant blue (CBB) staining.Further,all the changed proteins were positively identified via mass spectrometry (MS)/MS analysis. Of these,PGAM1 was significantly downregulated in HeLa cells after treatment with SAHA. Moreover,PGAM1 has been proven to be downregulated in another cervical cancer cell line (CaSki) by western blot analysis.Together,using proteomic tools,we identified several differentially expressed proteins that underwent SAHA-induced apoptosis. These changed proteins may provide some clues to a better understanding of the molecular mechanisms underlying SAHA-induced apoptosis in cervical cancer.